Physician profile
Devin P Schock
NPI 1649617382
$7,281.86
in general payments reported to CMS, 2019-2025
56 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $103 · 2021: $1,220 · 2022: $1,283 · 2023: $1,719 · 2024: $1,544 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.96 | 2021-2025 | Ubrelvy, Viberzi, Linzess |
| Novo Nordisk INC | $735.17 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $518.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $419.67 | 2020-2025 | Spravato, Xarelto |
| Kowa Pharmaceuticals America, INC. | $354.21 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Vanda Pharmaceuticals INC. | $289.64 | 2020-2025 | Fanapt, Hetlioz |
| Gilead Sciences, INC. | $284.57 | 2021-2025 | Descovy |
| Abbott Laboratories | $257.76 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $228.94 | 2021-2025 | Breztri, Flumist Quadrivalent, Farxiga |
| Pfizer INC. | $224.19 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203.82 | 2023-2025 | Caplyta |
| Amgen INC. | $198.01 | 2021-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $189.79 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $184.38 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $171.22 | 2023-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Schock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.